← News & updates

WHO Good Reliance Practices may guide NBCD discussions worldwide

News | 4 August 2020

In June, the World Health Organization (WHO) published a draft document on 'Good Reliance Practices' (GRP), which puts forth recommendations for the regulation of medicinal products. Intended for national regulatory authorities, the document is a practical guide for the management of clinical trial applications, product development and post-approval activities.



In the case of NBCDs, GRP can contribute to creating a robust and globally aligned regulatory framework by allocating the right expertise and resources at the right time. Therefore, and upon invitation, the NBCD Working Group provided input to the WHO supporting the case for the draft document with suggestions to further specify its use in complex regulatory cases such as NBCDs and nanomedicines in general.

The WHO will evaluate all comments received and following a second public consultation round, plans to present the final draft to the 55th Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP) in mid-October.

The principles and recommendations set out in the draft document have the potential to guide NBCD discussions going forwards, helping to increase efficiency and streamline regulatory efforts.

Share this page...